P Hersey
Overview
Explore the profile of P Hersey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
191
Citations
2894
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Jiang C, Lai F, Tay K, Croft A, Rizos H, Becker T, et al.
Cell Death Dis
. 2011 Mar;
1:e69.
PMID: 21364673
Bim is known to be critical in killing of melanoma cells by inhibition of the RAF/MEK/ERK pathway. However, the potential role of the most potent apoptosis-inducing isoform of Bim, Bim(S),...
12.
Hersey P, Smalley K, Weeraratna A, Bosenberg M, Zhang X, Haass N, et al.
Pigment Cell Melanoma Res
. 2011 Jan;
24(1):e1-15.
PMID: 21232023
The 2010 7th International Melanoma Congress sponsored by the Society for Melanoma Research and held in Sydney, Australia, was held together with the International Melanoma and Skin Cancer Centers group...
13.
Yang F, Tay K, Dong L, Thorne R, Jiang C, Yang E, et al.
Cell Death Differ
. 2010 Mar;
17(8):1354-67.
PMID: 20300110
Past studies have identified a number of distinct mechanisms that contribute to the resistance of melanoma cells against apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL). In this report we show...
14.
15.
Gogas H, Eggermont A, Hauschild A, Hersey P, Mohr P, Schadendorf D, et al.
Ann Oncol
. 2009 Jul;
20 Suppl 6:vi8-13.
PMID: 19617299
Biomarkers are tumour- or host-related factors that correlate with tumour biological behaviour and patient prognosis. High-throughput analytical techniques--DNA and RNA microarrays--have identified numerous possible biomarkers, but their relevance to melanoma...
16.
Schadendorf D, Algarra S, Bastholt L, Cinat G, Dreno B, Eggermont A, et al.
Ann Oncol
. 2009 Jul;
20 Suppl 6:vi41-50.
PMID: 19617297
Immunotherapy of metastatic melanoma consists of various approaches leading to specific or non-specific immunomodulation. The use of FDA-approved interleukin (IL)-2 alone, in combination with interferon alpha, and/or with various chemotherapeutic...
17.
Hersey P, Bastholt L, Chiarion-Sileni V, Cinat G, Dummer R, Eggermont A, et al.
Ann Oncol
. 2009 Jul;
20 Suppl 6:vi35-40.
PMID: 19617296
Chemotherapy, biological agents or combinations of both have had little impact on survival of patients with metastatic melanoma. Advances in understanding the genetic changes associated with the development of melanoma...
18.
Eggermont A, Testori A, Marsden J, Hersey P, Quirt I, Petrella T, et al.
Ann Oncol
. 2009 Jul;
20 Suppl 6:vi30-4.
PMID: 19617295
The lack of effective drugs in stage IV melanoma has impacted the effectiveness of adjuvant therapies in stage II/III disease. To date, chemotherapy, immunostimulants and vaccines have been used with...
19.
Beusterien K, Szabo S, Kotapati S, Mukherjee J, Hoos A, Hersey P, et al.
Br J Cancer
. 2009 Jul;
101(3):387-9.
PMID: 19603025
Background: No studies measure preference-based utilities in advanced melanoma that capture both intended clinical response and unintended toxicities associated with treatment. Methods: Using standard gamble, utilities were elicited from 140...
20.
Watson A, Middleton M, McGown G, Thorncroft M, Ranson M, Hersey P, et al.
Br J Cancer
. 2009 Apr;
100(8):1250-6.
PMID: 19367283
We evaluated the pharmacodynamic effects of the O(6)-methylguanine-DNA methyltransferase (MGMT) inactivator lomeguatrib (LM) on patients with melanoma in two clinical trials. Patients received temozolomide (TMZ) for 5 days either alone...